This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the U.S. I am a U.S. resident I am a patient outside the U.S.
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

Patient FAQ
Tips For Taking TASIGNA
Interactive Dosing Questionnaire

TIPS FOR TAKING TASIGNA

What’s your TASIGNA time?

Your patients probably already have a suitable window in their daily routines that is a perfect time to take their TASIGNA doses. The dosing questionnaire can help you and/or your patients find the best time to take TASIGNA.

With TASIGNA, just remember 12,2,1!1

TASIGNA 12,2,1 Dosing Schedule
  • 12: TASIGNA doses should be taken 12 hours apart with a glass of water
  • 2: Patients should fast for 2 hours before taking TASIGNA
  • 1: Patients should fast for 1 hour after taking TASIGNA

Use this interactive dosing questionnaire to create an individualized dosing guide for your patient, with examples of how other patients fit TASIGNA into their schedules.

TASIGNA can interact with certain foods and drugs1

TASIGNA Food Interactions

Avoid products or juices containing grapefruit, star fruit, and Seville oranges for as long as you are treating your Ph+ CML with TASIGNA.

TASIGNA Drug Interactions

Let your doctor know about all of the medications and over-the-counter supplements that you are taking.

If any of your doctors prescribe a new medication or you’re considering taking a new over-the-counter supplement, ask a doctor or pharmacist if it’s okay to take it with TASIGNA.


References:
1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; June 2011.
2. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of Bcr-Abl for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356.

TASIGNA Interactive Game

Use the interactive dosing questionnaire to find the best time to fit TASIGNA into your patients' schedules.

To see how TASIGNA is an optimized Bcr-Abl inhibitor that was designed to improve on imatinib, visit TASIGNA mechanism of action.2